Suggested Searches

photo of Amitoj Gill
812-945-4000

Amitoj Gill, MD

Hematology Oncology
Gender: Male
Accepting New Patients

Practice Locations

A:
Baptist Health Medical Group Hematology & Oncology
2210 Green Valley Road, Suite 1
New Albany, IN 47150
812-945-4000 812-941-5714
B:
Baptist Health Medical Group Hematology & Oncology
941 West McClain Avenue, Suite C
Scottsburg, IN 47170
812-945-4000 812-752-2555
C:
Baptist Health Medical Group Hematology & Oncology
101 Hospital Boulevard
Jeffersonville, IN 47130
812-945-4000 812-941-5714

Education

Fellowship

University of Louisville

Medical School

Educational Commission for Foreign Medical Graduates

Residency

Johns Hopkins University School of Medicine

Board Certifications

-

American Board of Internal Medicine

Hospital Affiliations

  • Baptist Health La Grange

Philosophy of Care

Baptist Health Medical Group is a comprehensive, multispecialty network of physicians and advanced practice clinicians. Our providers are committed to providing compassionate, patient-centered care and strive to treat our patients the way we would want to be treated, every time, at every Baptist Health location.

Research

  • Carcinoma, Non-Small-Cell Lung

    Pacific 4: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative NSCLC

    Trial Details
  • Early Cancer Detection (SIRB-23-0050)

    Adela CAMPERR: cfMeDIP-seq Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse (CAMPERR)

    Trial Details
  • Hematology

    READY 1: A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)

    Trial Details
  • Non-small Cell Lung Cancer (NSCLC)

    Pacific 9: A Phase III, double-blind, placebo-controlled, Randomized, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

    Trial Details